secwatch.observer — SEC 8-K summary
======================================

Issuer:     RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK:        0001649904
Form:       8-K
Filed at:   2023-05-02T23:59:59+00:00
Accession:  0001104659-23-054774
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rhythm Pharma Q1 revenue $11.5M, net loss $52.2M; BBS prescriptions over 300 since launch
--------------------------------------------------------------------------------

- Net product revenue $11.5M in Q1 2023 vs $1.5M YoY; net loss $52.2M ($0.92/sh) vs $52.8M ($1.05/sh).
- Over 300 new BBS prescriptions for IMCIVREE since June 2022 FDA approval; >100 written in Q1 2023.
- First patients dosed in pivotal Phase 3 hypothalamic obesity trial; enrollment completion expected Q1 2024.
- Cash position $294.6M at March 31, 2023, down from $333.3M; FY 2023 Non-GAAP OpEx guidance $200-220M.
- Launched IMCIVREE in Germany for BBS with federal reimbursement on April 24, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649904/000110465923054774/0001104659-23-054774-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649904/000110465923054774/tm2314243d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-054774

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer